A New Product to Join Our Portfolio

Within the scope of agreement between KONSINA and Sanofi Group, as from 1st December 2016 Valganciclovir is now part of KONSINA’s product portfolio inclusive of sales, marketing and promotional activities. Valganciclovir, produced in Zentiva’s Turkey facilities, is indicated for treatment of CMV retinitis in patients with AIDS and for the preventation of CMV diseases in solid organ transplantation patients

Respectfully announced to the public.

Konsina designed this website to provide general information to the public and Health Care Professionals. This information is not intended to replace your doctors, pharmacists or dentists recommendations. It is strongly recommended to follow your doctor's personal advice about your situation.